Open AccessATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
Author(s) -
David A. Reardon,
Thomas Kaley,
Jörg Dietrich,
Jennifer Clarke,
Gavin P. Dunn,
Michael Lim,
Tim Cloughesy,
Hui Gan,
Andrew Park,
Paul Schwarzenberger,
Toni Ricciardi,
Mary Macri,
Aileen Ryan,
Ralph Venhaus
Publication year - 2018
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noy148.033
Subject(s) - tolerability , bevacizumab , medicine , oncology , cohort , clinical endpoint , adverse effect , population , chemotherapy , clinical trial , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom